title: Intensive insulin therapy in the neurocritical care setting is associated with poor clinical outcomes.
abstract: BACKGROUND
  Studies devoted to intensive glucose control suggested that the intensive insulin therapy (IIT) approach could effectively reduce complications associated with critical illness. A program of IIT with the goal of achieving a blood glucose of 80-120 mg/dL was, therefore, adopted in this study. To explore the impact of this approach in patients admitted to a neurocritical care unit, we compared the short-term outcomes of patients treated before and after our policy change.
  
  
  METHODS
  Retrospectively extracted data from the electronic medical records of 1913 patients admitted between Feb 1, 2005 and Aug 30, 2006 were included in the standard insulin therapy group (SIT targeted to maintain blood glucose levels less than 150 mg/dL) and 1796 patients admitted between Sept 1, 2006 and March 30, 2008 were included in the IIT group (IIT-targeted to maintain blood glucose levels between 80 and 120 mg/dL).
  
  
  RESULTS
  Mean glucose levels were lower in the IIT compared to SIT (136.9 mg/dL, SD 47.6 vs. 143.8 mg/dL, SD 46.4); however, this strategy was also associated with an increased incidence of hypoglycemia (OR: 1.8, and 95% CI: 1.5-2.3). The likelihood of mortality increased proportionally as the severity of hypoglycemia worsened (any blood glucose value <70 mg/dL, OR: 3.26, and 95% CI: 2.52-4.22, any blood glucose <40, OR: 3.65, and 95% CI: 2.21-6.02, any blood glucose <20, OR: 6.25, and 95% CI: 2.41-16.23).
  
  
  CONCLUSIONS
  IIT was not only able to reduce overall mean glucose levels, but also resulted in significantly more episodes of hypoglycemia, increased mortality, and increased length of stay. The relationship between hypoglycemia and mortality indicates that efforts to control glucose levels should also aggressively avoid induction of hypoglycemia.
authors.affiliation: Duke University Medical Center, Durham, NC, USA. graff002@mc.duke.edu
authors.forename: Carmelo
authors.initials: C
authors.lastname: Graffagnino
authors.forename: Ananda R
authors.initials: AR
authors.lastname: Gurram
authors.forename: Bradley
authors.initials: B
authors.lastname: Kolls
authors.forename: DaiWai M
authors.initials: DM
authors.lastname: Olson
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D001927:Brain Diseases / Q000188:drug therapy* / Q000401:mortality; D001930:Brain Injuries / Q000188:drug therapy / Q000401:mortality; D002545:Brain Ischemia / Q000188:drug therapy / Q000401:mortality; D003422:Critical Care / Q000379:methods* / Q000706:statistics & numerical data; D016638:Critical Illness / Q000401:mortality; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000401:mortality; D007003:Hypoglycemia / Q000139:chemically induced / Q000401:mortality; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin